Healing the heart by manipulating microRNAs

Jaan Biotherapeutics is developing first-in-class therapies that repair damaged heart muscle and treat cardiovascular diseases by reactivating an endogenous regeneration process that has been shut down in the adult human heart during evolution, but is active in human fetal hearts.

Like Comment
Page of
Go to the profile of Jaan Biotherapeutics

Jaan Biotherapeutics

Jaan Biotherapeutics LLC (JBT), a preclinical stage company, is developing first-in-class regenerative therapies that reactive an evolutionary cardiac muscle regeneration process in human diseased adult heart that is active in human fetal tissue, but is inactive in the human adult heart. We have designed therapeutics that target carefully selected non-coding RNAs, known as microRNAS. MicroRNAs function in RNA silencing and post-transcriptional regulation of gene expression by modulating the activity of a number of genes and compensatory pathways. By modulating specific microRNAs, JBTs therapeutics reprogram a specific pool of cardiac myocytes in the adult heart to divide and potentially regenerate damaged heart muscle to treat cardiovascular diseases where cardiac muscle regeneration is required. JBT has two lead therapies that initially target three cardiovascular diseases: Ischemic heart disease (IHD)- Drug Candidate JN-101 Cardiomyopathy associated with Duchenne muscular dystrophy (DMD)-Drug Candidate JN-101 Familial hypertrophic cardiomyopathy (HCM)-Drug candidate JN-210 Our lead candidate, JN-101, is ready for initiation of Investigational New Drug Application Studies.

No comments yet.